Alpharetta, Ga. – July 09, 2019 – CSI Laboratories (CSI) and Synergy Capital Investments (Synergy) today announced the transition of a convertible note to equity stake in CSI, a state of the art, specialized cancer diagnostic center.
“The security purchase agreement, originally issued in 2017, supported a significant transformation around revenue cycle, sales and operational management that improved our profitability,” said Chief Executive Officer and Chief Financial Officer, Chris Wicker. “The note positioned CSI to expand capabilities through the implementation of cutting-edge informatics and the addition of the second testing facility in Jupiter, FL that opened earlier in 2019. We are very pleased to continue our partnership with Synergy as a shareholder and build on CSI’s robust performance.”
CSI executed a considerable financial turnaround in the past two years, and the financial outlook is positive for sustained planned growth.
Munir Karimi, Chief Executive Officer of Synergy, assumes a seat on the Board of Directors of CSI. Said Karimi, “We have been working closely with the CSI team for the past couple of years. This is an excellent time to participate on the equity side given their strong financial performance, outstanding executive guidance, and medical thought leadership. The investment reflects our excitement and optimism for CSI’s continued momentum and reinforces our support of CSI Laboratories.”